ADSCs capacity as in vitro anti-protein glycation factor in diabetic foot ulcers

• Grant number: 12/14573-0
• Support Opportunities: Regular Research Grants
• Start date: December 01, 2012
• End date: November 30, 2014
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Cesar Isaac
• Grantee: Cesar Isaac
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated researchers: Ana Paula Pereira Velosa ; Marisa Passarelli ; Sergio Catanozi ; Walcy Paganelli Rosolia Teodoro

Abstract

In the diabetic chronic ulcer repair process, wound repair failure is associated with abnormal cellular and molecular responses at all stages of the wound healing. Known factors such as dermal accumulation of advanced glycation end products (advanced glycation end products - AGEs) explains the chronic appearance of these lesions in diabetic patients. In the wound matrix, protein glycation is initiated spontaneously by non-enzymatic reactions between free amino groups and carbonyl groups of sugars. Adipose derived stem cells (ADSCs) are stem cells obtained from the stroma of white adipose tissue which produces biologically active substances that interfere in the production of collagen, fibronectin, vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). The present study was designed to evaluate the ability of ADSCs to modulate the activity of advanced glycation end products in cultured fibroblasts from granulation tissue of wounds present in the lower limbs of diabetic individuals. These results could stimulate new clinical trials on the treatment of this condition. (AU)